Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma

Figure 4

Validation on ARID1A’s ability to predict patients’ survival outcome. A, b: Difference of immunotherapy response rate between high-risk and low-risk group, predicted by TIDE and Immune cell AI algorithms, respectively. c: Alteration spectrum of 9 mutant and 4 copy number varied genes screened above. d: Mutation sites of ARID1A in EC. e: There were no difference of ARID1A mRNA expression between ARID1A mutant and wild groups. f: ARID1A mutant group showed a better survival outcome in UCEC (Uterine Corpus Endometrial Carcinoma) cohort. (ns: not significant; response and nonresponse: patient response to immunotherapy or vice versa; ARID1A-mut and ARID1A-wild: group with ARID1A mutation or vice versa).

(a)

(b)

(c)

(d)

(e)

(f)